TABLE OF CONTENTS

Volume 5, Issue 3 (April 2008)

Top

Papers

Climate of change continues in Canada

Jim Keon

J Generic Med 5: 167-174; advance online publication, February 5, 2008; doi:10.1057/jgm.2008.1

Pricing strategies of originator and generic medicines following patent expiry in Belgium

Michael Adriaen, Kristof De Witte and Steven Simoens

J Generic Med 5: 175-187; advance online publication, March 6, 2008; doi:10.1057/jgm.2008.8

How to make the most of IP due diligence in deals involving generics

Beverly W Lubit

J Generic Med 5: 189-199; advance online publication, February 26, 2008; doi:10.1057/jgm.2008.5

The value of patent term extensions to the pharmaceutical industry in the USA FREE

Charles Clift

J Generic Med 5: 201-208; advance online publication, March 4, 2008; doi:10.1057/jgm.2008.6

Pharmacists' views on generic medicines: A review of the literature

Nabil Abdo Al-Gedadi and Mohamed Azmi Hassali

J Generic Med 5: 209-218; advance online publication, March 4, 2008; doi:10.1057/jgm.2008.7

Top

US Case Reports

Aventis v Lupin: Obviousness of purified stereoisomers in view of mixtures thereof

Frederick H Rein and Joseph B Crystal

J Generic Med 5: 219-228; advance online publication, February 12, 2008; doi:10.1057/jgm.2008.2

Top

EU Case Reports

Supplementary protection certificates; atorvastatin; fexofenadine

Michael Burdon, Robert Stephen, Priya Vatvani, Catherine Katzka and Luke Hill

J Generic Med 5: 229-233; advance online publication, February 11, 2008; doi:10.1057/jgm.2008.3

Top

Acarbose: A case study in the forfeiture of the 180-day exclusivity

Paul A Braier

J Generic Med 5: 235-240; advance online publication, March 11, 2008; doi:10.1057/jgm.2008.9

Top

EU Legal and Regulatory Update

J Generic Med 5: 241-246; advance online publication, January 15, 2008; doi:10.1057/jgm.2007.33

Top

Patent Focus

Molecular form: Patentability of known active ingredients

Leighton Howard

J Generic Med 5: 247-253; doi:10.1057/jgm.2008.4